Catalent expert invited to share formulation development expertise at Aerosol School
11 April 2012 | By Catalent Pharma Solutions
Dr. Lei Mao, Project Director and Group Leader, R&D of Catalent Pharma Solutions to present...
List view / Grid view
News
Abbott’s HUMIRA® (adalimumab) approved in Europe for treatment of ulcerative colitis (UC)
11 April 2012 | By
The European Commission has approved HUMIRA®...
Corning to acquire majority of BD Discovery Labware
Corning Incorporated (NYSE: GLW) announced today that it has reached a definitive agreement with BD (Becton, Dickinson and Company) (NYSE:BDX) to acquire the majority of its Discovery Labware unit for approximately $730 million in cash. The acquisition is expected to be completed later this year, subject to customary closing conditions,…
Around the World in 80 ways – Catalent expert to present on clinical distribution supply chain at 2012 ISPE Japan
10 April 2012 | By Catalent Pharma Solutions
Esther Sadler-Williams will lead two discussions...
Amgen to acquire privately held KAI Pharmaceuticals
10 April 2012 | By Amgen
Amgen and KAI Pharmaceuticals have announced an agreement under which Amgen will acquire KAI...
Abbott receives approval for next-generation XIENCE PRIME™ drug eluting stent in Japan
9 April 2012 | By Abbott
Abbott announced it has received approval from the Japanese MHLW...
Roche disappointed with ISS recommendation
6 April 2012 | By Roche
Roche released the following statement in response to a report issued by Institutional Shareholder Services...
FDA approves Amyvid™
6 April 2012 | By Eli Lilly and Company
Amyvid is the first and only radioactive diagnostic agent approved for PET imaging of beta-amyloid neuritic plaques in the living brain...
FDA decides Teva is sole first-to-file on Provigil®
5 April 2012 | By Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA, is sole first-to-file for both Orange Book patents listed for Provigil® (modafinil)...
Sanofi and Regeneron announce regulatory and clinical update for Zaltrap® (aflibercept)
5 April 2012 | By Sanofi
The FDA has granted Priority Review of the BLA for the investigational agent Zaltrap®...
BASF and Catalent join forces to solve bioavailability challenges
4 April 2012 | By Catalent Pharma Solutions
Catalent Pharma Solutions and BASF have entered into a broad collaboration...
UCB and Amgen initiate sclerostin antibody Phase 3 program in patients with Postmenopausal Osteoporosis
4 April 2012 | By Amgen
The start of sclerostin antibody Phase 3 clinical trial program announced...
Lonza appoints Richard Ridinger as new CEO
At a meeting on 2 April 2012, the Board of Directors of Lonza elected Mr. Richard Ridinger as the new CEO of Lonza. Mr. Ridinger will become CEO of Lonza effective 1 May. Rolf Soiron was acting CEO ad interim, since the end of January.
Tecan granted patent for revolutionary NanoQuant Plate™
3 April 2012 | By kdm communications limited
The revolutionary design of Tecan’s NanoQuant Plate™ has been recognized with the granting of a new European patent...
A case study by Catalent expert to be presented at PDA Annual Meeting
3 April 2012 | By Catalent Pharma Solutions
“Challenging Technical Transfer of a Biopharmaceutical – the Product X Case Study”...
